MARKET

ANNX

ANNX

Annexon, Inc.
NASDAQ
1.750
-0.020
-1.13%
After Hours: 1.828 +0.078 +4.48% 19:59 05/13 EDT
OPEN
1.810
PREV CLOSE
1.770
HIGH
1.840
LOW
1.680
VOLUME
1.37M
TURNOVER
--
52 WEEK HIGH
7.85
52 WEEK LOW
1.285
MARKET CAP
192.00M
P/E (TTM)
-1.7399
1D
5D
1M
3M
1Y
5Y
1D
Annexon price target lowered to $14 from $20 at H.C. Wainwright
TipRanks · 15h ago
ANNEXON, INC. <ANNX.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $14 FROM $20
Reuters · 15h ago
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 17h ago
Annexon Is Maintained at Buy by Needham
Dow Jones · 18h ago
Annexon Price Target Cut to $11.00/Share From $16.00 by Needham
Dow Jones · 18h ago
Needham Maintains Buy on Annexon, Lowers Price Target to $11
Benzinga · 18h ago
Annexon Biosciences: Buy Rating Driven by Regulatory Milestones and Promising Pipeline Developments
TipRanks · 18h ago
U.S. RESEARCH ROUNDUP-ACI Worldwide, Expand Energy, First Solar
Reuters · 21h ago
More
About ANNX
More
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Recently
Symbol
Price
%Change

Webull offers Annexon Inc stock information, including NASDAQ: ANNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANNX stock methods without spending real money on the virtual paper trading platform.